Semaglutide 24 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, doubledummy, placebocontrolled, phase 3 trial
Pedrosa MR, Franco DR, Gieremek HW, Vidal CM, Bronzeri F, de Cassia Rocha A, de Carvalho Cara LG, Fogo SL, Eliaschewitz FG (2022) GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far
Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41)
In this blog, we will walk through exactly what Accutane is and explain the top five things you should know when you start taking this medication
Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease